Lifecore Net Debt from 2010 to 2025

LFCR Stock

6.55 0.03 0.46%

Lifecore Biomedical Net Debt yearly trend continues to be relatively stable with very little volatility. Net Debt is likely to grow to about 147.2 M this year. Net Debt is the total debt of Lifecore Biomedical minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

1996-02-29

Previous Quarter

131.3 M

Current Value

2.9 M

Quarterly Volatility

69.1 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Lifecore Biomedical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lifecore Biomedical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 6.4 M, Interest Expense of 21.8 M or Total Revenue of 140.1 M, as well as many indicators such as Price To Sales Ratio of 0.2, Dividend Yield of 0.0 or PTB Ratio of 0.74. Lifecore financial statements analysis is a perfect complement when working with Lifecore Biomedical Valuation or Volatility modules.

Check out the analysis of Lifecore Biomedical Correlation against competitors.

To learn how to invest in Lifecore Stock, please use our How to Invest in Lifecore Biomedical guide.

Latest Lifecore Biomedical's Net Debt Growth Pattern

Below is the plot of the Net Debt of Lifecore Biomedical over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Lifecore Biomedical's Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lifecore Biomedical's overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

Lifecore Net Debt Regression Statistics

	Arithmetic Mean	98,590,908
	Coefficient Of Variation	74.23
	Mean Deviation	64,479,783
	Median	121,898,000
	Standard Deviation	73,181,949
	Sample Variance	5355.6T
	Range	234.5M
	R-Value	0.79
	Mean Square Error	2168.8T
	R-Squared	0.62
	Significance	0.0003
	Slope	12,123,222
	Total Sum of Squares	80334T

Lifecore Net Debt History

	2025	147.2 M
	2024	140.2 M
	2023	121.9 M
	2022	151.4 M
	2021	151.5 M
	2020	220.1 M
	2019	220.8 M

Other Fundumenentals of Lifecore Biomedical

Net Debt To E B I T D A

Lifecore Biomedical Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Net Receivables	Intangible Assets	Common Stock	Current Deferred Revenue	Short Term Investments	Good Will	Net Tangible Assets	Long Term Debt	Net Invested Capital	Long Term Investments	Short Long Term Debt	Capital Stock	Net Working Capital	Property Plant Equipment
Total Assets		0.76	0.62	0.48	0.75	0.69	0.85	0.4	0.89	0.31	-0.66	-0.48	-0.66	0.69	0.24	0.21	0.25	0.04	0.26	-0.2	-0.08	0.15
Total Stockholder Equity	0.76		0.0	0.91	0.8	0.08	0.45	0.17	0.77	0.63	-0.42	-0.46	-0.64	0.89	0.72	-0.34	0.71	0.63	0.69	-0.61	-0.6	0.66
Net Debt	0.62	0.0		-0.28	0.16	0.94	0.84	0.56	0.46	-0.31	-0.41	-0.21	-0.24	0.02	-0.44	0.67	-0.41	-0.67	-0.38	0.31	0.6	-0.53
Retained Earnings	0.48	0.91	-0.28		0.6	-0.27	0.22	0.11	0.52	0.72	-0.09	-0.38	-0.46	0.87	0.9	-0.55	0.87	0.83	0.86	-0.82	-0.75	0.83
Accounts Payable	0.75	0.8	0.16	0.6		0.32	0.48	0.2	0.89	0.53	-0.5	-0.46	-0.54	0.71	0.4	-0.33	0.48	0.48	0.57	-0.28	-0.56	0.58
Total Liab	0.69	0.08	0.94	-0.27	0.32		0.78	0.38	0.53	-0.22	-0.57	-0.25	-0.3	0.09	-0.43	0.69	-0.37	-0.62	-0.37	0.4	0.49	-0.48
Total Current Assets	0.85	0.45	0.84	0.22	0.48	0.78		0.69	0.76	0.16	-0.56	-0.47	-0.56	0.39	-0.02	0.35	-0.05	-0.29	0.03	-0.08	0.28	-0.15
Short Term Debt	0.4	0.17	0.56	0.11	0.2	0.38	0.69		0.44	-0.03	-0.2	-0.33	-0.31	0.05	-0.21	-0.03	-0.26	-0.19	-0.05	-0.13	0.29	-0.09
Net Receivables	0.89	0.77	0.46	0.52	0.89	0.53	0.76	0.44		0.34	-0.66	-0.53	-0.69	0.6	0.25	-0.14	0.27	0.19	0.41	-0.22	-0.25	0.32
Intangible Assets	0.31	0.63	-0.31	0.72	0.53	-0.22	0.16	-0.03	0.34		-0.19	-0.48	-0.43	0.68	0.71	-0.39	0.69	0.65	0.66	-0.59	-0.61	0.65
Common Stock	-0.66	-0.42	-0.41	-0.09	-0.5	-0.57	-0.56	-0.2	-0.66	-0.19		0.5	0.83	-0.16	0.17	-0.17	0.17	0.21	0.16	-0.13	-0.19	0.18
Current Deferred Revenue	-0.48	-0.46	-0.21	-0.38	-0.46	-0.25	-0.47	-0.33	-0.53	-0.48	0.5		0.57	-0.41	-0.24	0.18	-0.25	-0.19	-0.31	0.26	0.18	-0.25
Short Term Investments	-0.66	-0.64	-0.24	-0.46	-0.54	-0.3	-0.56	-0.31	-0.69	-0.43	0.83	0.57		-0.39	-0.18	0.13	-0.14	-0.13	-0.18	0.42	0.06	-0.14
Good Will	0.69	0.89	0.02	0.87	0.71	0.09	0.39	0.05	0.6	0.68	-0.16	-0.41	-0.39		0.81	-0.19	0.83	0.66	0.75	-0.63	-0.66	0.71
Net Tangible Assets	0.24	0.72	-0.44	0.9	0.4	-0.43	-0.02	-0.21	0.25	0.71	0.17	-0.24	-0.18	0.81		-0.49	0.97	0.85	0.91	-0.77	-0.81	0.84
Long Term Debt	0.21	-0.34	0.67	-0.55	-0.33	0.69	0.35	-0.03	-0.14	-0.39	-0.17	0.18	0.13	-0.19	-0.49		-0.47	-0.8	-0.65	0.53	0.73	-0.76
Net Invested Capital	0.25	0.71	-0.41	0.87	0.48	-0.37	-0.05	-0.26	0.27	0.69	0.17	-0.25	-0.14	0.83	0.97	-0.47		0.87	0.91	-0.72	-0.88	0.87
Long Term Investments	0.04	0.63	-0.67	0.83	0.48	-0.62	-0.29	-0.19	0.19	0.65	0.21	-0.19	-0.13	0.66	0.85	-0.8	0.87		0.88	-0.72	-0.96	0.97
Short Long Term Debt	0.26	0.69	-0.38	0.86	0.57	-0.37	0.03	-0.05	0.41	0.66	0.16	-0.31	-0.18	0.75	0.91	-0.65	0.91	0.88		-0.72	-0.9	0.94
Capital Stock	-0.2	-0.61	0.31	-0.82	-0.28	0.4	-0.08	-0.13	-0.22	-0.59	-0.13	0.26	0.42	-0.63	-0.77	0.53	-0.72	-0.72	-0.72		0.59	-0.71
Net Working Capital	-0.08	-0.6	0.6	-0.75	-0.56	0.49	0.28	0.29	-0.25	-0.61	-0.19	0.18	0.06	-0.66	-0.81	0.73	-0.88	-0.96	-0.9	0.59		-0.97
Property Plant Equipment	0.15	0.66	-0.53	0.83	0.58	-0.48	-0.15	-0.09	0.32	0.65	0.18	-0.25	-0.14	0.71	0.84	-0.76	0.87	0.97	0.94	-0.71	-0.97

Click cells to compare fundamentals

About Lifecore Biomedical Financial Statements

Lifecore Biomedical shareholders use historical fundamental indicators, such as Net Debt, to determine how well the company is positioned to perform in the future. Although Lifecore Biomedical investors may analyze each financial statement separately, they are all interrelated. The changes in Lifecore Biomedical's assets and liabilities, for example, are also reflected in the revenues and expenses on on Lifecore Biomedical's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Net Debt	140.2 M	147.2 M
Net Debt To EBITDA	2.04	2.54

Additional Tools for Lifecore Stock Analysis

When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lifecore Net Debt from 2010 to 2025

Latest Lifecore Biomedical's Net Debt Growth Pattern

Lifecore Net Debt Regression Statistics

Lifecore Net Debt History

Other Fundumenentals of Lifecore Biomedical

Lifecore Biomedical Net Debt component correlations

About Lifecore Biomedical Financial Statements

Additional Tools for Lifecore Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY